Cargando…

Epigenetics of Inflammatory Bowel Diseases

Inflammatory bowel diseases are multifactorial, chronic, continuous, relapsing, and immune-mediated diseases of the gastrointestinal tract. It has been believed that mechanisms underlying inflammatory bowel diseases include genetic predisposition, environmental factors, and altered immune response t...

Descripción completa

Detalles Bibliográficos
Autores principales: Törüner, Murat, Ünal, Nalan Gülşen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish Society of Gastroenterology 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334590/
https://www.ncbi.nlm.nih.gov/pubmed/37158530
http://dx.doi.org/10.5152/tjg.2023.22515
_version_ 1785070889761505280
author Törüner, Murat
Ünal, Nalan Gülşen
author_facet Törüner, Murat
Ünal, Nalan Gülşen
author_sort Törüner, Murat
collection PubMed
description Inflammatory bowel diseases are multifactorial, chronic, continuous, relapsing, and immune-mediated diseases of the gastrointestinal tract. It has been believed that mechanisms underlying inflammatory bowel diseases include genetic predisposition, environmental factors, and altered immune response to the gut microbiome. The epigenetic modulation takes place via chromatin modifications, including phosphorylation, acetylation, methylation, sumoylation, and ubiquitination. The methylation levels of colonic tissue were found well correlated to blood samples in inflammatory bowel diseases. Moreover, the methylation level of specific genes was different between Crohn’s disease and ulcerative colitis. It has been shown that the enzymes affecting histone modifications like histone deacetylases and histone acetyltransferases do not act solely on histones but also affect the acetylation of many proteins such as p53 and STAT3. It has been already shown that a nonselective histone deacetylase inhibitor, Vorinostat (SAHA), which is currently being used in several cancer treatments, showed anti-inflammatory activities in mouse models. Among epigenetic alterations, long non-coding RNAs and microRNAs play significant roles in T-cell maturation, differentiation, activation, and senility. The long non-coding RNA and microRNA expression profiles can perfectly separate inflammatory bowel disease patients from healthy controls and are remarked as biomarkers of inflammatory bowel diseases. Overall, many studies have shown that epigenetic inhibitors can target significant signal pathways in the pathogenesis of inflammatory bowel diseases, and the impact of epigenetic inhibitors is being studied in clinical trials. In conclusion, exploring more epigenetic pathways regarding inflammatory bowel disease pathogenesis will help us to discover therapeutic targets and new drugs and agents targeting miRNAs in inflammatory bowel diseases. In general, discovering epigenetic targets could improve the diagnosis and treatment of inflammatory bowel diseases.
format Online
Article
Text
id pubmed-10334590
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Turkish Society of Gastroenterology
record_format MEDLINE/PubMed
spelling pubmed-103345902023-07-12 Epigenetics of Inflammatory Bowel Diseases Törüner, Murat Ünal, Nalan Gülşen Turk J Gastroenterol Review Inflammatory bowel diseases are multifactorial, chronic, continuous, relapsing, and immune-mediated diseases of the gastrointestinal tract. It has been believed that mechanisms underlying inflammatory bowel diseases include genetic predisposition, environmental factors, and altered immune response to the gut microbiome. The epigenetic modulation takes place via chromatin modifications, including phosphorylation, acetylation, methylation, sumoylation, and ubiquitination. The methylation levels of colonic tissue were found well correlated to blood samples in inflammatory bowel diseases. Moreover, the methylation level of specific genes was different between Crohn’s disease and ulcerative colitis. It has been shown that the enzymes affecting histone modifications like histone deacetylases and histone acetyltransferases do not act solely on histones but also affect the acetylation of many proteins such as p53 and STAT3. It has been already shown that a nonselective histone deacetylase inhibitor, Vorinostat (SAHA), which is currently being used in several cancer treatments, showed anti-inflammatory activities in mouse models. Among epigenetic alterations, long non-coding RNAs and microRNAs play significant roles in T-cell maturation, differentiation, activation, and senility. The long non-coding RNA and microRNA expression profiles can perfectly separate inflammatory bowel disease patients from healthy controls and are remarked as biomarkers of inflammatory bowel diseases. Overall, many studies have shown that epigenetic inhibitors can target significant signal pathways in the pathogenesis of inflammatory bowel diseases, and the impact of epigenetic inhibitors is being studied in clinical trials. In conclusion, exploring more epigenetic pathways regarding inflammatory bowel disease pathogenesis will help us to discover therapeutic targets and new drugs and agents targeting miRNAs in inflammatory bowel diseases. In general, discovering epigenetic targets could improve the diagnosis and treatment of inflammatory bowel diseases. Turkish Society of Gastroenterology 2023-05-01 /pmc/articles/PMC10334590/ /pubmed/37158530 http://dx.doi.org/10.5152/tjg.2023.22515 Text en © 2023 authors https://creativecommons.org/licenses/by/4.0/ Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by/4.0/)
spellingShingle Review
Törüner, Murat
Ünal, Nalan Gülşen
Epigenetics of Inflammatory Bowel Diseases
title Epigenetics of Inflammatory Bowel Diseases
title_full Epigenetics of Inflammatory Bowel Diseases
title_fullStr Epigenetics of Inflammatory Bowel Diseases
title_full_unstemmed Epigenetics of Inflammatory Bowel Diseases
title_short Epigenetics of Inflammatory Bowel Diseases
title_sort epigenetics of inflammatory bowel diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10334590/
https://www.ncbi.nlm.nih.gov/pubmed/37158530
http://dx.doi.org/10.5152/tjg.2023.22515
work_keys_str_mv AT torunermurat epigeneticsofinflammatoryboweldiseases
AT unalnalangulsen epigeneticsofinflammatoryboweldiseases